Considering that up to 30% of patients develop inhibitors against exogenous FVIII [45], immunogenicity is an important issue in the routine prophylaxis of hemophilia A. Although the true immunogenicity of hBS910 needs to be evaluated clinically, it is noteworthy that two different in silico systems predicted hBS910 to be non-immunogenic. This evidence concerns the gene F8 and hemophilia A.